| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DLAT |
| Uniprot No | P10515 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 93-640aa |
| 氨基酸序列 | KVPLPSLSPTMQAGTIARWEKKEGDKINEGDLIAEVETDKATVGFESLEECYMAKILVAEGTRDVPIGAIICITVGKPEDIEAFKNYTLDSSAAPTPQAAPAPTPAATASPPTPSAQAPGSSYPPHMQVLLPALSPTMTMGTVQRWEKKVGEKLSEGDLLAEIETDKATIGFEVQEEGYLAKILVPEGTRDVPLGTPLCIIVEKEADISAFADYRPTEVTDLKPQVPPPTPPPVAAVPPTPQPLAPTPSAPCPATPAGPKGRVFVSPLAKKLAVEKGIDLTQVKGTGPDGRITKKDIDSFVPSKVAPAPAAVVPPTGPGMAPVPTGVFTDIPISNIRRVIAQRLMQSKQTIPHYYLSIDVNMGEVLLVRKELNKILEGRSKISVNDFIIKASALACLKVPEANSSWMDTVIRQNHVVDVSVAVSTPAGLITPIVFNAHIKGVETIANDVVSLATKAREGKLQPHEFQGGTFTISNLGMFGIKNFSAIINPPQACILAIGASEDKLVPADNEKGFDVASMMSVTLSCDHRVVDGAVGAQWLAEFRKYLE |
| 预测分子量 | 62.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与DLAT重组蛋白相关的文献摘要概括(注：文献为虚拟示例，实际引用需核实具体来源)：
1. **《Structural insights into human dihydrolipoamide acetyltransferase (DLAT) in pyruvate dehydrogenase complex》**
- **作者**: Zhang et al. (2020)
- **摘要**: 通过重组表达人源DLAT蛋白，结合X射线晶体学技术解析其三维结构，揭示其在丙酮酸脱氢酶复合体(PDC)中的催化机制及与底物结合的关键位点。
2. **《Autoantigen DLAT as a biomarker in type 1 diabetes: Production and validation of recombinant DLAT for antibody detection》**
- **作者**: Pullen et al. (2018)
- **摘要**: 研究利用重组DLAT蛋白开发新型免疫检测方法，证实其在1型糖尿病患者血清中作为自身抗原的潜在诊断价值，并探讨其与疾病进展的关联性。
3. **《Recombinant DLAT protein enhances mitochondrial function in Alzheimer's disease cell models》**
- **作者**: Johnson & Lee (2019)
- **摘要**: 通过体外表达DLAT重组蛋白，验证其恢复阿尔茨海默病细胞模型中丙酮酸脱氢酶复合体活性、改善线粒体能量代谢的作用机制。
4. **《Targeting DLAT-mediated metabolic reprogramming in cancer immunotherapy》**
- **作者**: Chen et al. (2021)
- **摘要**: 研究重组DLAT蛋白在肿瘤微环境中的免疫调节功能，发现其通过调控T细胞代谢增强抗肿瘤免疫反应的潜在治疗策略。
(注：以上文献信息为示例性内容，实际研究需参考真实发表的学术论文。)
**Background of DLAT Recombinant Protein**
Dihydrolipoamide acetyltransferase (DLAT), a key component of the pyruvate dehydrogenase complex (PDC), plays a central role in cellular energy metabolism. Located in the mitochondrial matrix, DLAT catalyzes the transfer of an acetyl group from pyruvate to coenzyme A, a critical step linking glycolysis to the citric acid cycle. This enzymatic activity is essential for aerobic respiration, enabling the conversion of glucose into ATP. Dysregulation of DLAT has been implicated in metabolic disorders, neurodegenerative diseases, and cancer, highlighting its biological and clinical significance.
Recombinant DLAT protein is produced using genetic engineering techniques, typically through heterologous expression in systems like *E. coli* or mammalian cell cultures. The process involves cloning the DLAT gene into an expression vector, optimizing conditions for protein synthesis, and employing purification methods such as affinity chromatography. Recombinant technology ensures high purity, specificity, and scalability, addressing challenges associated with isolating native DLAT from biological tissues.
Research applications of recombinant DLAT span structural biology, drug discovery, and disease mechanism studies. Its use in crystallography and cryo-EM has advanced understanding of PDC architecture and DLAT’s catalytic mechanisms. In drug development, recombinant DLAT serves as a target for metabolic disorder therapies or a tool for screening inhibitors/activators. Notably, DLAT autoantibodies are biomarkers in rare autoimmune disorders like anti-mitochondrial antibody (AMA)-positive diseases, driving diagnostic assay development.
Furthermore, recombinant DLAT contributes to studying mitochondrial dysfunction in conditions such as Alzheimer’s disease and diabetes. Its therapeutic potential is being explored in metabolic engineering and gene therapy to restore PDC activity in genetic deficiencies. Overall, recombinant DLAT is a vital tool for bridging fundamental biochemistry with translational medicine.
×
